Effects of neuroserpin on clinical outcomes and inflammatory markers in Chinese patients with acute ischemic stroke

References

• Hastings GA, Coleman TA, Haudenschild CC, et al. Neuroserpin, a brain-associated inhibitor of tissue plasminogen activator is localized primarily in neurons Implications for the regulation of motor learning and neuronal survival. J Biol Chem. 1997;272:33062–33067.10.1074/jbc.272.52.33062
   PubMed Web of Science ®Google Scholar
• Krueger SR, Ghisu G-P, Cinelli P, et al. Expression of neuroserpin, an inhibitor of tissue plasminogen activator, in the developing and adult nervous system of the mouse. J neurosci. 1997;17:8984–8996.
   PubMed Web of Science ®Google Scholar
• Osterwalder T, Contartese J, Stoeckli E, et al. Neuroserpin, an axonally secreted serine protease inhibitor. EMBO j. 1996;15:2944.
   PubMed Web of Science ®Google Scholar
• Yepes M, Sandkvist M, Wong MK, et al. Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood. 2000;96:569–576.
   PubMed Web of Science ®Google Scholar
• Cinelli P, Madani R, Tsuzuki N, et al. Neuroserpin, a neuroprotective factor in focal ischemic stroke. Mol Cell Neurosci. 2001;18:443–457. Epub 2002/04/02.10.1006/mcne.2001.1028
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang L, Yepes M, et al. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation. 2002;106:740–745.10.1161/01.CIR.0000023942.10849.41
   PubMed Web of Science ®Google Scholar
• Lebeurrier N, Liot G, Lopez-Atalaya JP, et al. The brain-specific tissue-type plasminogen activator inhibitor, neuroserpin, protects neurons against excitotoxicity both in vitro and in vivo. Mol Cell Neurosci. 2005;30:552–558. Epub 2005/10/08.10.1016/j.mcn.2005.09.005
   PubMed Web of Science ®Google Scholar
• Lebeurrier N, Launay S, Macrez R, et al. Anti-Mullerian-hormone-dependent regulation of the brain serine-protease inhibitor neuroserpin. J Cell Sci. 2008;121:3357–3365. Epub 2008/09/18.10.1242/jcs.031872
   PubMed Web of Science ®Google Scholar
• Wu J, Echeverry R, Guzman J, et al. Neuroserpin protects neurons from ischemia-induced plasmin-mediated cell death independently of tissue-type plasminogen activator inhibition. Am J Pathol. 2010;177:2576–2584. Epub 2010/09/25.10.2353/ajpath.2010.100466
   PubMed Web of Science ®Google Scholar
• Gelderblom M, Neumann M, Ludewig P, et al. Deficiency in serine protease inhibitor neuroserpin exacerbates ischemic brain injury by increased postischemic inflammation. PLoS One. 2013;8:e63118. Epub 2013/05/10.10.1371/journal.pone.0063118
   PubMed Web of Science ®Google Scholar
• Liang W, Chuan-Zhen L, Qiang D, et al. Reductions in mRNA of the neuroprotective agent, neuroserpin, after cerebral ischemia/reperfusion in diabetic rats. Brain Res. 2004;1015:175–180. Epub 2004/06/30.10.1016/j.brainres.2004.04.053
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang Y, Asakawa T, et al. Neuroprotective Effect of Neuroserpin in Oxygen-Glucose Deprivation-and Reoxygenation-Treated Rat Astrocytes In Vitro. PLoS One. 2015;10:e0123932.10.1371/journal.pone.0123932
   PubMed Web of Science ®Google Scholar
• Yang X, Asakawa T, Han S, et al. Neuroserpin protects rat neurons and microglia-mediated inflammatory response against oxygen-glucose deprivation- and reoxygenation treatments in an in vitro study. Cell Physiol Biochem. 2016;38:1472–1482.10.1159/000443089
   PubMed Web of Science ®Google Scholar
• Rodriguez-Gonzalez R, Millan M, Sobrino T, et al. The natural tissue plasminogen activator inhibitor neuroserpin and acute ischaemic stroke outcome. Thromb Haemost. 2011;105:421–429. Epub 2010/12/22.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Gonzalez R, Sobrino T, Rodriguez-Yanez M, et al. Association between neuroserpin and molecular markers of brain damage in patients with acute ischemic stroke. J Transl Med. 2011;9:58. Epub 2011/05/17.10.1186/1479-5876-9-58
   PubMed Web of Science ®Google Scholar
• 2010 CfetCGftEMoPwAIS. Chinese Guidelines for the Early Management of Patients with Acute Ischemic Stroke 2010. Chin J Neurol. 2010;43:146–153.
   Google Scholar
• Vogt G, Laage R, Shuaib A, et al. Initial lesion volume is an independent predictor of clinical stroke outcome at day 90 an analysis of the virtual international stroke trials archive (VISTA) database. Stroke. 2012;43:1266–1272.10.1161/STROKEAHA.111.646570
   PubMed Web of Science ®Google Scholar
• Brott T, Adams H, Olinger CP, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864–870.10.1161/01.STR.20.7.864
   PubMed Web of Science ®Google Scholar
• Lyden PD, Hantson L. Assessment scales for the evaluation of stroke patients. J Stroke Cerebrovascular Diseases. 1998;7:113–127.10.1016/S1052-3057(98)80138-9
   PubMedGoogle Scholar
• Asakawa T, Fang H, Sugiyama K, et al. Human behavioral assessments in current research of Parkinson’s disease. Neurosci Biobehav Rev. 2016;68:741–772.10.1016/j.neubiorev.2016.06.036
   PubMed Web of Science ®Google Scholar
• Asakawa T, Fang H, Sugiyama K, et al. Animal behavioral assessments in current research of Parkinson’s disease. Neurosci Biobehav Rev. 2016;65:63–94.10.1016/j.neubiorev.2016.03.016
   PubMed Web of Science ®Google Scholar
• Fang X, Namba H, Akamine S, et al. Methylenetetrahydrofolate reductase gene polymorphisms in patients with cerebral hemorrhage. Neurol Res. 2005;27:73–76.10.1179/016164105X18313
   PubMed Web of Science ®Google Scholar
• Rodriguez-Gonzalez R, Agulla J, Perez-Mato M, et al. Neuroprotective effect of neuroserpin in rat primary cortical cultures after oxygen and glucose deprivation and tPA. Neurochem Int. 2011;58:337–343 . Epub 2010/12/18.10.1016/j.neuint.2010.12.006
   PubMed Web of Science ®Google Scholar
• Yepes M, Lawrence DA. Neuroserpin: a selective inhibitor of tissue-type plasminogen activator in the central nervous system. Thrombosis Haemostasis-Stuttgart. 2004;91:457–464.
   PubMed Web of Science ®Google Scholar
• Dziedzic T. Systemic inflammation as a therapeutic target in acute ischemic stroke. Expert Rev Neurother. 2015;15:523–531.10.1586/14737175.2015.1035712
   PubMed Web of Science ®Google Scholar
• Beamer NB, Coull BM, Clark WM, et al. Interleukin-6 and interleukin-1 receptor antagonist in acute stroke. Annals Neurol. 1995;37:800–805.10.1002/ana.410370614
   PubMed Web of Science ®Google Scholar
• Acalovschi D, Wiest T, Hartmann M, et al. Multiple levels of regulation of the interleukin-6 system in stroke. Stroke. 2003;34:1864–1869.10.1161/01.STR.0000079815.38626.44
   PubMed Web of Science ®Google Scholar
• Waje-Andreassen U, Kråkenes J, Ulvestad E, et al. IL-6: an early marker for outcome in acute ischemic stroke. Acta Neurol Scand. 2005;111:360–365.10.1111/ane.2005.111.issue-6
   PubMed Web of Science ®Google Scholar
• Audebert HJ, Rott MM, Eck T, et al. Systemic inflammatory response depends on initial stroke severity but is attenuated by successful thrombolysis. Stroke. 2004;35:2128–2133.10.1161/01.STR.0000137607.61697.77
   PubMed Web of Science ®Google Scholar
• Vila N, Castillo J, Dávalos A, et al. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke. 2000;31:2325–2329.10.1161/01.STR.31.10.2325
   PubMed Web of Science ®Google Scholar